Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 7, 2013, Pages 1033-1039

  Rezvani, Andrew R ^a,b   McCune, Jeannine S ^a,b   Storer, Barry E ^a,b   Batchelder, Ami ^a   Kida, Aiko ^a   Deeg, H Joachim ^a,b   McDonald, George B ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Busulfan; Cyclophosphamide; Hepatotoxicity; Myelofibrosis; Transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; METHOTREXATE; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CONTINUOUS INFUSION; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; STEADY STATE;

ADULT; AGED; BUSULFAN; CASE-CONTROL STUDIES; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INJECTIONS, INTRAVENOUS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84879377700     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.04.005     Document Type: Article

References (35)

1. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997, 89:3055-3060.
2. Slattery J.T., Sanders J.E., Buckner C.D., et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995, 16:31-42.
3. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005, 105:1810-1814.
4. Deeg H.J., Scott B.L., Fang M., et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 2012, 120:1398-1408.
5. DeLeve L.D. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996, 24:830-837.
6. DeLeve L.D., Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology 2000, 60:143-154.
7. McDonald G.B., Slattery J.T., Bouvier M.E., et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003, 101:2043-2048.
8. McCune J.S., Woodahl E.L., Furlong T., et al. Apilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients. Cancer Chemother Pharmacol 2012, 69:263-272.
9. Pidala J., Kim J., Anasetti C., et al. Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. Bone Marrow Transplant 2011, 46:641-649.
10. McCune J.S., Batchelder A., Guthrie K.A., et al. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther 2009, 85:615-622.
11. Geraci J.P., Mariano M.S., Jackson K.L. Radiation hepatology of the rat: microvascular fibrosis and enhancement of liver dysfunction by diet and drugs. Radiat Res 1992, 129:322-332.
12. Wang X., Kanel G.C., DeLeve L.D. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat. Hepatology 2000, 31:428-434.
13. Meresse V., Hartmann O., Vassal G., et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992, 10:135-141.
14. Kerbauy F.R., Tirapelli B., Akabane H., Oliveira J.S. The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans. Bone Marrow Transplant 2009, 43:883-885.
15. Cantoni N., Gerull S., Heim D., et al. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT. Bone Marrow Transplant 2011, 46:344-349.
16. Wong K.M., Atenafu E.G., Kim D., et al. Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:1589-1599.
17. Yeh R.F., Pawlikowski M.A., Blough D.K., et al. Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hemtopoietic cell transplant recipients. Biol Blood Marrow Transplant 2012, 18:265-272.
18. McCune J.S., Batchelder A., Deeg H.J., et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007, 13:853-862.
19. Slattery J.T., Risler L.J. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 1998, 20:543-549.
20. McDonald G.B., Sharma P., Matthews D.E., et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984, 4:116-122.
21. Kahl C., Storer B.E., Sandmaier B.M., et al. Relapse risk among patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007, 110:2744-2748.
22. Qiu R., Yao A., Vicini P., et al. Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard. Clin Pharmacol Ther 2004, 76:270-280.
23. Jenke A., Freiberg-Richter J., Wilhelm S., et al. Accidental busulfan overdose during conditioning for stem cell transplantation. Bone Marrow Transplant 2005, 35:125-128.
24. O'Donnell P.H., Artz A.S., Undevia S.D., et al. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leukemia Lymphoma 2010, 51:2240-2249.
25. Perkins J.B., Kim J., Anasetti C., et al. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:1099-1107.
26. Zhang H., Graiser M., Hutcherson D.A., et al. Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:1287-1294.
27. LeMaistre J.A., Bachier C., Smith B., et al. Once-daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant. JOncol Pharm Pract 2012, 18:17-22.
28. Williams C.B., Day S.D., Reed M.D., et al. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biol Blood Marrow Transplant 2004, 10:614-623.
29. Grochow L.B. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993, 20:18-25.
30. Dix S.P., Wingard J.R., Mullins R.E., et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996, 17:225-230.
31. Nilsson C., Forsman J., Hassan Z., et al. Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice. Exp Hematol 2005, 33:380-387.
32. Sadeghi B., Jansson M., Hassan Z., et al. The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model. Bone Marrow Transplant 2008, 41:895-904.
33. Kashyap A., Wingard J., Cagnoni P., et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002, 8:493-500.
34. Cornelissen J.J., van Putten W.L., Verdonck L.F., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 2007, 109:3658-3666.
35. Anasetti C., Logan B.R., Lee S.J., et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. NEngl J Med 2012, 367:1487-1496.